The standard of care for a hemophilia A patient has changed from on-demand treatment, defined as infusing factor concentrate in response to a bleed, to prophylactic treatment, in which patients receive regular replacement of FVIII to maintain a minimum effective FVIII level [15]. The gene discussed is F8; the disease is hemophilia A.